Clinical trials: Hepatic Chemotherapy
Hepatocellular Carcinoma (HCC)
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.
- Trial name
- HAICI (NCT06741020)
- Testing
- Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
There are limited treatment options for patients with unresectable hepatocellular carcinoma (HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1.
- Trial name
- NCT04994236
- Testing
- Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Hui-Chuan Sun
Biliary Tract Cancer
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
- Trial name
- AB02 (NCT07221253)
- Testing
- Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
- Where
- 183 sites in United States, Australia and 17 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Cholangiocarcinoma
Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
The purpose of this study is to assess efficacy and tolerance of intra-hepatic administration of Yttrium 90-labelled microsphere (Theraspheres®, Nordion) in association with intravenous chemotherapy with Gemcitabin and Cisplatin…
- Trial name
- MispheC (NCT01912053)
- Testing
- Therasphere® in association with Gemcitabine and Cisplatin
- Where
- 7 sites in France
- Volunteers
- 41 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)
The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT02290977
- Testing
- Scheduled interval TACE - RT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC
Prospective single arm, single center observational study to evaluate factors which were easily available from preoperative examination for predicting therapeutic effects and clinical prognosis of hepatic artery infusion…
- Trial name
- NCT05002452
- Testing
- Search of factors predicting therapeutic effects and prognosis
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency
- Trial name
- NCT03814005
- Testing
- Azacitidine, Pevonedistat
- Where
- 8 sites in United States, Spain
- Volunteers
- 17 people
- Sponsor
- Takeda
Adebrelimab, Hepatocellular Carcinoma
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Primary liver cancer mainly consists of three different pathologic types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and hybrid HCC-ICC, of which HCC accounts for 90%.
- Trial name
- NCT06405061
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection.
- Trial name
- CONV3RSION (NCT07483359)
- Testing
- HAIC + Tislelizumab +lenvatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- First Hospital of China Medical University
Malignant Biliary Tract Tumors
A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors
3. Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion…
- Trial name
- NCT07790445
- Testing
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhai Wenlong
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, Lenvatinib
- Trial name
- NCT06632093
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 84 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Steatohepatitis
PET-MR Study of Fatty Liver
This is a pilot, translational study designed to explore the feasibility of molecular imaging with FBA-A20FMDV2, radiolabelled with fluorine-18 ([18F]-FBA-A20FMDV2), in patients with SH and CASH in hepatic metastatic disease.
- Trial name
- iDOSH (NCT04063826)
- Testing
- PET MRI
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular…
- Trial name
- NCT04044313
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shi Ming
Hepatocellular Carcinoma
Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm worldwide and the third most frequent cause of death from cancer in the world.
- Trial name
- NCT05491889
- Testing
- trans arterial chemoembolization
- Volunteers
- 30 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
- Trial name
- NCT06244225
- Testing
- Donafenib； Sintilimab； HAIC
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Resectable Hepatocellular Carcinoma
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT05519410
- Testing
- Sintilimab and Lenvatinib, HAIC-FOLFOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital